HealthLeaders Media September 20, 2022
Forty-four percent of hospitals view the 340B Drug Pricing Program as a critical revenue source.
The original purpose of the 340B Drug Pricing Program was to help ensure patients with cancer could afford the life-saving drugs they’d need, however, a lack of regulation and oversight has gotten in the way of the original mission, and new research from the Community Oncology Alliance found that safety net hospitals have hiked the cost of cancer drugs almost five times their 340B purchase price.
The Community Oncology Alliance examined 49 top acute care hospitals with many uninsured patients and found that these hospitals price the top oncology drugs at 4.9 times their 340B acquisition costs, assuming a 34.7% discount, which the report calls...
Today's Sponsors
Today's Sponsor